Kettering Health now offers Daraxonrasib, a newly approved treatment for pancreatic cancer, one of the deadliest and most difficult cancers to treat. Clinical studies showed the drug significantly improved survival compared to standard treatment options.

Before receiving FDA approval Aug. 26, 2026, Kettering Health was among 12 hospitals in the state selected to provide Daraxonrasib through an Expanded Access Program, allowing eligible patients to receive the treatment sooner.

Expanded Access Programs help connect patients with promising therapies before full FDA approval, providing new options for those facing serious illnesses with limited treatment pathways.

“Being selected for the Expanded Access Program reflects the expertise of our oncology and pharmacy teams and our commitment to bringing innovative treatments to patients as quickly as possible,” said Brendan Rasor, PharmD, manager of pharmacy infusion at Kettering Health. “Now, with FDA approval, even more patients have access to a treatment that offers new hope in the fight against pancreatic cancer.”